R. Hilker et al., Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia, J NE NE PSY, 71(2), 2001, pp. 193-199
Objectives-The advent of botulinum neurotoxin type A (BoNT/A) gave rise to
substantial progress in the treatment of focal dystonias. In the light of t
he high costs of the toxin and the necessity to establish valid outcome ind
ices for this treatment apart from sheer reduction of dystonic muscle tone
and posture, the impact of focal dystonia and its treatment with BoNT/A on
patients' health related quality of life (HRQL) was determined.
Methods-Fifty patients with cranial and cervical dystonia treated long term
with BoNT/A were enrolled in a prospective, open labelled cohort study. Th
e HRQL was assessed using the EuroQo1 (EQ-5D) and the short form 36 health
survey questionnaire (SF-36) at baseline before BoNT/A injections and at tw
o follow up visits after 6 and 12 weeks covering one BoNT/A treatment perio
d with maximum effect size at the first follow up.
Results-Compared with a general population sample, a considerable negative
impact of focal dystonia on HRQL was found in patients under investigation.
In both disease types, BoNT/A treatment led to a significant improvement i
n several HRQL dimensions, in particular providing moderate to marked effec
t sizes in the fields of mental health and pain. The impairment of HRQL due
to pain as well as the BoNT/A induced improvement within this SF-36 subsco
re were significantly higher in patients with cervical dystonia. Under BoNT
/A therapy, no correlation was found between changes of clinical outcome sc
ores and HRQL measures.
Conclusions-The data confirm that BoNT/A is able to induce a significant, b
ut temporary amelioration of several aspects of HRQL in both types of focal
dystonia. This may substantially contribute to the patients' subjective be
nefit from the therapy. Moreover, the data provide further arguments to acc
ept high costs of the BoNT/A treatment in these severely handicapped patien
ts, as a consequence of its considerable benefit on quality of life.